2/8/2013

Amgen intends to commercialize biosimilar versions of six of the biggest-selling biologic drugs including Humira and Remicade, the main rivals of its own rheumatoid arthritis treatment Enbrel, starting in 2017, CEO Robert Bradway said. The biotech firm sees biosimilars as a multi-billion-dollar opportunity, and it expects to become a major player in the market once the approval pathway is finalized.

Full Story:
Reuters

Related Summaries